Oncology Clinical Trials in Canton, OH

As of June 2026, 64 paid clinical trials are recruiting for Oncology in Canton, Ohio. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

64 clinical trials for Oncology

·Clear filters·↓ Download CSV

XTX301 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

11 locations incl. Sacramento

Sponsor: Xilio Development, Inc.

Sex: All·Age: 18+

Code: NCT05684965·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of SGR-1505 in Mature B-Cell Neoplasms

for Mature B-Cell Neoplasm

16 locations incl. Gilbert

Sponsor: Schrödinger, Inc.

Sex: All·Age: 18+

Code: NCT05544019·Phase 1·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

475 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

for Solid Tumor, Adult

4 locations incl. Detroit

Sponsor: Sairopa B.V.

Sex: All·Age: 18+

Code: NCT05856981·Phase 1·Recruiting

Apply to this trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for Breast Cancer

15 locations incl. Orlando

Sponsor: Incyclix Bio

Sex: All·Age: 18+

Code: NCT05735080·Phase 1, Phase 2·Recruiting

Apply to this trial

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

for Advanced Solid Tumors

4 locations incl. Cerritos

Sponsor: Acrotech Biopharma Inc.

Sex: All·Age: 18+

Code: NCT07036133·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

for Hypogammaglobulinemia

7 locations incl. Huntington Park

Sponsor: Grifols Therapeutics LLC

Sex: All·Age: 18+

Code: NCT05645107·Phase 3·Recruiting

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

128 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting

Apply to this trial

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

for Small Cell Lung Cancer

11 locations incl. Encinitas

Sponsor: Chipscreen Biosciences, Ltd.

Sex: All·Age: 18+

Code: NCT05271292·Phase 1, Phase 2·Recruiting

Apply to this trial

GEMINI-NSCLC: NSCLC Biomarker Study

for Non-Small Cell Lung Cancer

58 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05236114·Recruiting

Apply to this trial

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

for Colorectal Cancer

20 locations incl. Fort Smith

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05234177·Recruiting

Apply to this trial

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

4 locations incl. Birmingham

Sponsor: Telios Pharma, Inc.

Sex: All·Age: 18+

Code: NCT05280509·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

for Myelofibrosis

22 locations incl. Duarte

Sponsor: Disc Medicine, Inc

Sex: All·Age: 18+

Code: NCT05320198·Phase 1, Phase 2·Recruiting

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

843 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting

Apply to this trial

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

for Relapsed Diffuse Large B-cell Lymphoma

17 locations incl. Fountain Valley

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)

Sex: All·Age: 18+

Code: NCT04920617·Phase 2·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

for Acute Myeloid Leukemia

21 locations incl. Fountain Valley

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04093570·Phase 2·Enrolling By Invitation

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

for Hematologic Malignancies

Drug: Venetoclax

3 locations incl. Detroit

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT03557619·Phase 1·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

for Triple Negative Breast Cancer

3 locations incl. Columbus

Sponsor: Jina Pharmaceuticals Inc.

Sex: Female·Age: 18 - 65

Code: NCT03671044·Phase 3·Recruiting

Apply to this trial

Integrated Cancer Repository for Cancer Research

for Pancreatic Cancer

42 locations incl. Greenwood Village

Sponsor: University of Nebraska

Sex: All·Age: 19 - 110·Accepts healthy volunteers

Code: NCT02012699·Recruiting

Apply to this trial

Molecular Genetics Studies of Cancer Patients and Their Relatives

for Malignant Neoplasm

35 locations incl. Phoenix

Sponsor: City of Hope Medical Center

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT04185935·Recruiting

Apply to this trial

Conditions in Oncology (Canton, OH)

Non-small cell lung cancer (NSCLC)· 12 Solid tumor· 11 Breast cancer· 9 Cancer (any)· 7 Ovarian cancer· 5 Small cell lung cancer· 4 Colorectal cancer· 4 Endometrial cancer· 4 Multiple myeloma· 4 Myelodysplastic syndromes (MDS)· 4 Head and neck cancer· 4 Prostate cancer· 3 Bladder cancer· 3 Myelofibrosis· 3 Non-Hodgkin lymphoma· 3 Hematologic malignancy· 3 Triple-negative breast cancer· 2 Lung cancer· 2 Pancreatic cancer· 2 Esophageal cancer· 2 Liver cancer· 2 Kidney cancer· 2 Chronic lymphocytic leukemia (CLL)· 2 Diffuse large B-cell lymphoma (DLBCL)· 2 Follicular lymphoma· 2 Mantle cell lymphoma· 2 Melanoma· 2 Skin cancer· 2 Thyroid cancer· 2 Sarcoma· 2 Metastatic breast cancer· 1 HER2-negative breast cancer· 1 Colon cancer· 1 Rectal cancer· 1 Gastric cancer· 1 Cervical cancer· 1 Acute myeloid leukemia (AML)· 1 Chronic myelomonocytic leukemia· 1 Leukemia (other)· 1 Small lymphocytic lymphoma· 1 Burkitt lymphoma· 1 Mesothelioma· 1 Neuroendocrine tumors· 1